Received: 21 December 2021
Accepted: 28 June 2022
First Online: 14 September 2022
: The project was conducted according to the guidelines of the Declaration of Helsinki, and reviewed by the Institutional Review Board of the University of Nevada Las Vegas and determined to be exempt (protocol 1428464-5, 5/15/2019). Informed consent was obtained from all subjects involved in the project. Participants electronically reviewed and signed the informed consent form prior to participation in the survey and were able to ask any clarifying questions before completing the consent process.
: Not applicable.
: The funders had no role in the design of the project; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. ACS's research is in part funded by Gilead. She also serves as a consultant and is on the advisory board for Gilead. ACS receives non-research support from Gilead, Abbvie, Merck, bioLytical Sciences, and Guardian. The remaining authors of the manuscript have no competing interests to declare.